Silencing HMGB1 expression inhibits adriamycin's heart toxicity via TLR4 dependent manner through MAPK signal transduction

Taskin E., Guven C., Kaya S. T., Sariman M., EMRENCE Z., Ekmekci S. S., ...Daha Fazla

JOURNAL OF BUON, cilt.25, sa.1, ss.554-565, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 25 Sayı: 1
  • Basım Tarihi: 2020
  • Dergi Adı: JOURNAL OF BUON
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.554-565
  • Anahtar Kelimeler: adriamycin, HMGB1, AMPK, TLR4, apoptosis, cardiac muscle cell, MITOCHONDRIAL DYSFUNCTION, INDUCED CARDIOTOXICITY, DOXORUBICIN, AMPK, CELLS, LIVER
  • İstanbul Üniversitesi Adresli: Evet

Özet

Purpose: Adriamycin (APR) is a commonly used anti-cancer drug. ADR has toxic effects on cardiomyocytes and leads to heart failure. However, the underlying mechanism(s) by which ADR causes heart failure is still not clarified exactly. The aim of present study is to investigate whether ADR-induced heart failure is mediated via HMGB1/TLR4 to initiate the apoptosis through MAPK/AMPK pathways.